A Randomized Phase II Trial of Interferon + GM-CSF Versus K562/GM-CSF Vaccination in CML Patients Achieving a Complete Cytogenetic Response to Frontline Tyrosine Kinase Inhibitor Therapy
Phase: PHASE2
Conditions: Leukemia
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

 
i 
 
J05121 
 
Title:
 
Principal Investigator: 
Co-Investigators:
Consenters:
Statistician:
Research Nurse:
Data Manager: 
DATE:
NCT00363649
NCT00363649
NCT00363649

 
ii 
 
SCHEMA 
PH+ CML Patients with CCR on 
TKI (56 patients) 
PCR +      
PCR - 
PCR -
PCR +
PCR -
PCR + 

 
iii 
 
GM-CSF
   K562-GM-CSF Vaccine

 
iv 
 

 
5 
 
α

 
6 
 
    
 

 
7 
 

 
8 
 

 
9 
 
 
 

 
10 
 
    
 

 
11 
 

 
12 
 
in vitro
WT-1

 
13 
 


 
14 
 

 
15 
 

 
16 
 
in situ

 
17 
 

 
18 
 

 
19 
 


 

 
20 
 

 
21 
 
 
 

 
22 
 

 
23 
 





 
24 
 
 
 




 
25 
 





 
26 
 
 
 
 

 
27 
 

 
28 
 




 
29 
 
Study Arm A: 

 
30 
 
Study Arm B: 

 
31 
 

 
32 
 
in vitro

 
33 
 
   

 
34 
 

 
35 
 

 
36 
 

 
37 
 
   

 
38 
 

 
39 
 

 
40 
 

 
41 
 

 
42 
 

 
43 
 

 
44 
 

 
45 
 

 
46 
 

 
47 
 

 
48 
 



 
49 
 

 
50 
 
Introduction:
 
Experience with CML
Probe:  
 

 
51 
 
Previous experience with Research
If yes
If no, 
 
Assessment of Understanding of CML Randomized Trial 
 
 
Decision-Making Process 
Decision Satisfaction
Advice to Others Considering Enrollment

 
52 
 
Closing 
 
Demographics 
 
Mark all that apply
 
 
Thank you for your time and thoughts